Celcuity Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Celcuity de winst en omzet met respectievelijk 27.6% en 73.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 32.9% per jaar.

Belangrijke informatie

27.6%

Groei van de winst

32.9%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	73.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Jul 18

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Jan 27

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Sep 21

Celcuity: Nipping The Oncogenic Bud

Jul 08

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

Mar 14

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

Jan 20

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Dec 23

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

Nov 29

Celcuity EPS beats by $0.03

Nov 09

Winst- en omzetgroeiprognoses

NasdaqCM:CELC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	50	-159	-88	-159	6
12/31/2025	1	-144	-94	-131	7
12/31/2024	N/A	-105	-70	-77	7
9/30/2024	N/A	-94	-74	-74	N/A
6/30/2024	N/A	-83	-67	-66	N/A
3/31/2024	N/A	-73	-58	-58	N/A
12/31/2023	N/A	-64	-54	-54	N/A
9/30/2023	N/A	-57	-45	-45	N/A
6/30/2023	N/A	-49	-41	-41	N/A
3/31/2023	N/A	-45	-43	-43	N/A
12/31/2022	N/A	-41	-36	-36	N/A
9/30/2022	N/A	-36	-33	-33	N/A
6/30/2022	N/A	-31	-27	-27	N/A
3/31/2022	N/A	-35	-24	-24	N/A
12/31/2021	N/A	-30	-20	-20	N/A
9/30/2021	N/A	-25	-16	-16	N/A
6/30/2021	N/A	-22	-14	-14	N/A
3/31/2021	N/A	-10	-8	-8	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-8	-7	-6	N/A
12/31/2019	N/A	-7	-6	-6	N/A
9/30/2019	N/A	-7	-6	-6	N/A
6/30/2019	N/A	-7	-7	-6	N/A
3/31/2019	N/A	-7	-7	-6	N/A
12/31/2018	N/A	-7	-7	-6	N/A
9/30/2018	N/A	-7	-6	-6	N/A
6/30/2018	N/A	-7	N/A	-6	N/A
3/31/2018	N/A	-7	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	N/A	-5	N/A	-5	N/A
6/30/2017	N/A	-5	N/A	-4	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CELC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CELC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CELC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CELC ( 73.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CELC ( 73.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CELC naar verwachting over 3 jaar hoog zal zijn

Celcuity Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.7% to US$29.50

Price target increased by 11% to US$27.40

Price target decreased to US$24.00

Price target decreased to US$30.50

Recent updates

Celcuity Inc. to Report Q3, 2024 Results on Nov 14, 2024

Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Celcuity Inc. to Report Q2, 2024 Results on Aug 14, 2024

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity Inc. has completed a Follow-on Equity Offering in the amount of $60.0005 million.

New major risk - Shareholder dilution

Celcuity Inc. Announces Plan to Initiate A Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Inc. to Report Q1, 2024 Results on May 15, 2024

Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?

Price target increased by 7.7% to US$29.50

Celcuity Inc., Annual General Meeting, May 09, 2024

Celcuity Inc. to Report Q4, 2023 Results on Mar 27, 2024

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

Price target increased by 11% to US$27.40

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q3, 2023 Results on Nov 13, 2023

Celcuity Inc. announced that it expects to receive $50 million in funding

Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Independent Director recently bought US$103k worth of stock

Celcuity Inc. to Report Q1, 2023 Results on May 15, 2023

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Celcuity to Present Additional Data for Gedatolisib At the 2022 San Antonio Breast Cancer Symposium

Price target decreased to US$24.00

Insufficient new directors

Celcuity Inc. Appoints Polly A. Murphy to its Audit Committee and Its Compensation Committee

Celcuity Inc. to Report Q3, 2022 Results on Nov 10, 2022

Celcuity Inc. Appoints Polly Murphy to Board of Directors

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Celcuity Inc. to Report Q2, 2022 Results on Aug 11, 2022

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Insufficient new directors

Price target decreased to US$30.50

Celcuity Inc. to Report Q1, 2022 Results on May 16, 2022

Celcuity Inc., Annual General Meeting, May 12, 2022

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Celcuity: Nipping The Oncogenic Bud

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

New 90-day high: US$17.80

New 90-day high: US$14.95

Celcuity Inc. Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

New 90-day high: US$11.97

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

New 90-day high: US$6.55

Celcuity EPS beats by $0.03

Celcuity Inc. to Report Q2, 2020 Results on Aug 10, 2020

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 2000 Dynamic Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell Small Cap Completeness Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 3000 Growth Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven